Spinal Modulation, a company out of Menlo Park, California, received the European CE Mark for its neurostimulation system for help in managing chronic intractable pain. The leads of the device deliver signals to the primary sensory neurons located within the dorsal root ganglion (DRG).
Unlike dorsal column spinal cord stimulation, the Spinal Modulation system breaks the pain signal’s path even before it enters the spinal cord.
Results of a multicenter prospective trial using the Spinal Modulation system were presented last weekend at the North American Neuromodulation Society’s annual meeting in Las Vegas.
“The Spinal Modulation system has provided substantial benefit to a number of my patients with chronic intractable pain that have not had adequate pain relief with other Spinal Cord Stimulation (SCS) systems. For example, patients with chronic intractable pain in the lower extremities are typically very difficult to treat with existing SCS systems. With the Spinal Modulation System, I have seen very encouraging results in patients with this type of pain condition,” said Dr. Liong Liem, Director of the Pain Management Practice at Sint Antonius Hospital in The Netherlands and one of two presenters at NANS.
Company homepage: Spinal Modulation…